ClinConnect ClinConnect Logo
Search / Trial NCT00256893

Fibromyalgia Study In Adults

Launched by GLAXOSMITHKLINE · Nov 21, 2005

Trial Information

Current as of May 17, 2025

Completed

Keywords

Pain Intensity Numerical Rating Scale Fibromyalgia

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • Diagnosis of primary fibromyalgia as defined by the American College of Rheumatology (ACR).
  • Females of childbearing potential will only be eligible if taking adequate contraceptive measures.
  • Other co-existent chronic pain conditions such as osteoarthritis, will not exclude the subject if the pain associated with the condition is less severe than the pain of fibromyalgia.
  • Only subjects experiencing moderate/severe pain (pain intensity score \>= 4 on the pain numerical rating scale) will be eligible for this study.
  • Subjects that are generally well.
  • Have the ability to discontinue prohibited medications for the duration of the study.
  • Exclusion criteria:
  • Subjects with 'flare' of arthritic conditions.
  • Evidence of clinically significant medical conditions including cardiovascular conditions (e.g. postural hypotension, and raised blood pressure, ECG abnormalities).
  • History of drug and/or alcohol abuse or major depression.

About Glaxosmithkline

GlaxoSmithKline (GSK) is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. With a strong focus on research and development, GSK specializes in pharmaceuticals, vaccines, and consumer health products. The company is committed to advancing innovative therapies and preventive measures across various therapeutic areas, including respiratory, oncology, immunology, and infectious diseases. GSK's collaborative approach and rigorous clinical trial processes underscore its dedication to delivering safe and effective healthcare solutions that meet the needs of patients worldwide.

Locations

Milano, Lombardia, Italy

Kuopio, , Finland

Roma, Lazio, Italy

Benevento, Campania, Italy

Bruxelles, , Belgium

Mikkeli, , Finland

Truro, Cornwall, United Kingdom

Heidelberg, Baden Wuerttemberg, Germany

Diepenbeek, , Belgium

Huettenberg, Hessen, Germany

Zwolle, , Netherlands

Jyvaskyla, , Finland

Cambridge, Cambridgeshire, United Kingdom

Frederiksberg, , Denmark

Merksem, , Belgium

Lomme, , France

Paris, , France

Fellbach, Baden Wuerttemberg, Germany

Bad Hersfeld, Hessen, Germany

Mölndal, , Sweden

Poole, Dorset, United Kingdom

Patients applied

0 patients applied

Trial Officials

GSK Clinical Trials

Study Director

GlaxoSmithKline

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials